Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Aflibercept in Recurrent or Persistent CNV

Response to Aflibercept After Previous Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Age-related macular degeneration (AMD) and diabetic retinopathy are among the most common disorders causing visual disability in elderly people. AMD leads to dysfunction and loss of photoreceptors in the central retina. Neovascular AMD (nAMD) affects visual function early in the disease process. The purpose of the study is to evaluate the effect of switching from ranibizumab therapy to the current routine therapy using aflibercept in eyes with treatment naive, recurrent or persistent nAMD, treatment naive diabetic retinopathy and pretreated diabetic retinopathy. 20 patients with recurrent or persistent nAMD, previously treated with intravitreal ranibizumab for up to one year will be included in this trial. Patients will be examined in monthly intervals over 12 months follow-up. Examinations carried out will include: Best-corrected visual acuity (BCVA) using ETDRS charts at 4m distance, Reading Performance (RP), Standard ophthalmic examinations (SOE incl. funduscopy and applanation tonometry), Optical coherence tomography (OCT), Autofluorescence fundus image (AF) \& red-free autofluorescence fundus image (RF), Color fundus photography (CFP), Fluorescein angiography and indocyaningreen angiography (FLA/ICG), Microperimetry (MP), as well as Non-invasive OCT based optical angiography (AngioVue).

Who May Be Eligible (Plain English)

Who May Qualify: Adults ≥ 50 years - Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year - BCVA \>= 20/400 in the study eye using ETDRS - Willingness and ability to comply with regular visits - Signed willing to sign a consent form Who Should NOT Join This Trial: - Any surgical treatment of the eye within 3 months prior to baseline in the study eye - History of uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma mediation) - Aphakia or absence of the posterior capsule (excluding YAG-capsulotomy) in the study eye - Retinal pigment epithelial tear involving the macula in the study eye Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: Adults ≥ 50 years * Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year * BCVA \>= 20/400 in the study eye using ETDRS * Willingness and ability to comply with regular visits * Signed informed consent Exclusion Criteria: * Any surgical treatment of the eye within 3 months prior to baseline in the study eye * History of uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma mediation) * Aphakia or absence of the posterior capsule (excluding YAG-capsulotomy) in the study eye * Retinal pigment epithelial tear involving the macula in the study eye

Treatments Being Tested

DRUG

Aflibercept

Locations (1)

Medical University of Vienna
Vienna, Austria